



1/15

MEDIUM	STATUS	CA 15-3 U / mg OF PROTEIN	erb UNITS / mg OF PROTEIN	p53 PMOL / mg OF PROTEIN	CD PMOL / mg OF PROTEIN	EGFR FMOL / mg OF PROTEIN	TOTAL PROTEIN mg / ml
SALIVA	CONTROLS (n=15)	2.27 ± 1.45	NOT DETECTABLE	177.1 ± 61.3	26.29 ± 17.22	1.03 ± 0.69	1.25 ± 0.82
	BENIGN (n=8)	2.22 ± 1.95	NOT DETECTABLE	180.7 ± 70.78	40.57 ± 13.05	0.37 ± 0.31	1.44 ± 0.92
	Ca IN SITU (n=12)	5.26 ± 4.12*	51.3 ± 43.96*	134.6 ± 63.8	34.5 ± 27.95	0.92 ± 0.8	1.71 ± 0.79
SERUM	CONTROLS (n=15)	16.17 ± 4.64	NOT DETECTABLE	14.2 ± 7.9	67.5 ± 35.61	8.5 ± 8.45	24.54 ± 13.86
	BENIGN (n=8)	15.25 ± 5.04	NOT DETECTABLE	14.63 ± 8.8	45.0 ± 20.98	3.52 ± 1.89	27.33 ± 14.23
	Ca IN SITU (n=12)	24.68 ± 10.9**	81.68 ± 111.77*	8.9 ± 7.7	63.17 ± 38.4	5.63 ± 3.10	29.23 ± 11.08

FIG. 1



2 / 15




FIG. 2



3 / 15




FIG. 3



4 / 15




FIG. 4



5 / 15




FIG. 5



6 / 15




FIG. 6



7 / 15




FIG. 7



8 / 15

MEAN AND STANDARD ERROR OF THE MEAN (S.E.M.) VALUES FOR c-erbB-2

CHARACTERISTICS	HEALTHY CONTROLS			BENIGN TUMORS			MALIGNANT TUMORS		
	n	AGE	MEAN (S.E.M.)	n	AGE	MEAN (S.E.M.)	n	AGE	MEAN (S.E.M.)
SALIVA c-erbB-2	57	39.6	94.70 (± 8.39)	41	45.0	99.72 (± 10.94)	30	50.8	222.22 (± 19.22)
SALIVA c-erbB-2 (UNITS / mg PROTEIN)	57	39.6	71.13 (± 6.07)	41	45.0	63.75 (± 7.00)	30	50.8	143.58 (± 11.53)
SALIVARY PROTEIN (mg / ml)	56	39.3	1.48 (± 0.09)	41	45.0	1.58 (± 0.08)	30	50.8	1.67 (± 0.10)
SALIVARY CA 15-3 (UNITS / ml)	42	38.0	3.19 (± 0.52)	33	43.9	7.23 (± 1.58)	30	50.8	10.90 (± 3.44)
SALIVARY FLOW RATES (ml / min.)	56	39.6	1.90 (± 0.12)	41	44.3	1.48 (± 0.12)	30	50.8	1.15 (± 0.13)
SERUM c-erbB-2	57	39.6	1472.15 (± 78.78)	41	44.3	1515.63 (± 155.48)	30	50.8	3490.67 (± 364.48)
SERUM c-erbB-2 (UNITS / mg PROTEIN)	57	39.6	28.04 (± 0.63)	41	44.3	33.05 (± 3.44)	30	50.8	85.97 (± 9.31)
SERUM CA 15-3 (UNITS / ml)	42	38.0	10.88 (± 0.74)	33	43.9	15.91 (± 0.88)	30	50.8	41.49 (± 10.65)
SERUM PROTEIN (mg / ml)	56	39.3	53.04 (± 1.41)	44	44.3	42.90 (± 1.16)	30	50.8	42.15 (± 1.58)

FIG. 8



9 / 15

FREQUENCY DISTRIBUTION FOR QUESTIONNAIRE DATA

CHARACTERISTIC	CONTROLS	BENIGN TUMORS	MALIGNANT TUMORS	p-VALUE
n	57	44	30	—
TOBACCO USAGE	—	—	—	2.40E-06
YES	3	15	16	—
NO	54	29	14	—
RACE	—	—	—	0.00063
CAUCASIAN	38	13	12	—
AFRICAN-AMERICAN	19	31	18	—
SYSTEMIC DISEASES	—	—	—	0.334
YES	16	17	10	—
NO	41	23	20	—
PRESCRIBED MEDICATIONS	—	—	—	0.449
YES	25	23	16	—
NO	32	18	14	—
MENOPAUSAL STATUS	—	—	—	0.00016
PREMENOPAUSAL	40	19	9	—
PERIMENOPAUSAL	0	10	17	—
POSTMENOPAUSAL	17	15	4	—

FIG. 9



10 / 15

MEAN AND STANDARD ERROR OF THE MEAN (S.E.M.) VALUES
 VALUES FOR c-erbB-2 AMONG VARYING MALIGNANT TUMOR STAGES

CHARACTERISTIC	SALIVA		SERUM	
	n	c-erbB-2 (UNITS /ml) MEAN (S.E.M.)	c-erbB-2 UNITS / mg PROTEIN MEAN (S.E.M.)	c-erbB-2 UNITS / mg PROTEIN MEAN (S.E.M.)
T1	7	211.15 (±25.91)	133.75 (±10.27)	95.57 (±16.83)
> T1	16	190.50 (±19.36)	137.01 (±17.85)	89.32 (±14.60)

MEAN AND STANDARD ERROR OF THE MEAN (S.E.M.) VALUES
 VALUES FOR c-erbB-2 AMONG NODE POSITIVE AND NODE NEGATIVE CANCER PATIENTS

TUMOR SIZES	c-erbB-2		c-erbB-2	
	n	c-erbB-2 (UNITS /ml) MEAN (S.E.M.)	c-erbB-2 UNITS / ml MEAN (S.E.M.)	c-erbB-2 UNITS / mg PROTEIN MEAN (S.E.M.)
NODE NEGATIVE	16	192.70 (±21.02)	119.52 (±12.74)	87.44 (± 8.83)
NODE POSITIVE	7	227.25 (±14.36)	192.42 (±29.19)	126.63 (±49.54)

FIG. 10



11 / 15

CUTOFF VALUES, SENSITIVITY, SPECIFICITY, AND PERCENT AREA UNDER CURVE
FOR SALIVARY AND SERUM c-erbB-2 AND CA 15-3 CONCENTRATIONS

CHARACTERISTICS	CUTOFF VALUE	SENSITIVITY	SPECIFICITY	PERCENT AREA UNDER CURVE
SALIVA c-erbB-2	110	0.87	0.65	75.7
SALIVA c-erbB-2 (UNITS / mg PROTEIN)	100	0.77	0.77	76.7
SALIVARY CA 15-3	4	0.62	0.79	70.5
SERUM c-erbB-2	2000	0.94	0.60	76.7
SERUM c-erbB-2 (UNITS / mg PROTEIN)	50	0.84	0.68	76.0
SERUM CA 15-3	20	0.75	0.44	62.2

FIG. 11



12 / 15




FIG. 12a




FIG. 12b



13 / 15




FIG. 13a




FIG. 13b



14 / 15




FIG. 14a




FIG. 14b



15 / 15




FIG. 15




FIG. 16